Literature DB >> 15508130

Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.

Miriam Böckmann1, Matthias Drosten, Brigitte M Pützer.   

Abstract

BACKGROUND: Adenovirus efficiently infects a broad range of target cells, thereby preventing selective gene transfer. Moreover, several cell types and tissues including primary tumors are refractory to adenoviral infection, mainly because of low expression levels of coxsackie-adenovirus receptor (CAR). Thus, identification of cancer-selective ligands which yield gene transfer to neoplastic cells by minimizing transduction of normal cells is a key issue for successful cancer therapy.
METHODS: We initially analyzed adenoviral receptor expression in human medullary thyroid carcinoma (MTC) cells. MTC cell-specific peptides were isolated by biopanning a phage display peptide library on cultured cancer cells and on tumors in vivo and further characterized.
RESULTS: We found significant differences in CAR and alphav-integrin protein levels between MTC-derived TT cells in vitro and established xenograft tumors in mice, indicating a lack of alphav-integrin expression on growing tumors. MTC-specific candidates were identified by performing three rounds of subtraction. Selected phages showed up to 22-fold higher binding efficiency for TT cells when compared with wild-type M13 phage or other human cell lines and tumor tissue in vivo. Homing to TT cells of the best binding phage was clearly blocked in the presence of specific peptide, whereas no phage competition was observed with an unspecific peptide. The best binding peptide mediated efficient internalization of the phage. Importantly, specific binding and internalization was also mediated by the identified peptide within the adenoviral context.
CONCLUSIONS: Our results indicate that the identified ligand should be suitable to improve selectivity of adenoviral gene transfer to medullary thyroid tumors in vivo. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15508130     DOI: 10.1002/jgm.648

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  9 in total

Review 1.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

2.  Potential of phage-displayed peptide library technology to identify functional targeting peptides.

Authors:  Lauren Rh Krumpe; Toshiyuki Mori
Journal:  Expert Opin Drug Discov       Date:  2007-04       Impact factor: 6.098

Review 3.  Bacteriophages and medical oncology: targeted gene therapy of cancer.

Authors:  Babak Bakhshinejad; Marzieh Karimi; Majid Sadeghizadeh
Journal:  Med Oncol       Date:  2014-07-11       Impact factor: 3.064

Review 4.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

Authors:  Kathlynn C Brown
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

6.  Identification of peptide ligands for targeting to the blood-brain barrier.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Gert Storm; Wim E Hennink; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-02-17       Impact factor: 4.200

Review 7.  Targeting Tumors with Small Molecule Peptides.

Authors:  Andrew G Cheetham; Daniel Keith; Pengcheng Zhang; Ran Lin; Hao Su; Honggang Cui
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

Review 8.  Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.

Authors:  Julia Reetz; Ottmar Herchenröder; Brigitte M Pützer
Journal:  Viruses       Date:  2014-04-02       Impact factor: 5.048

Review 9.  Designer Oncolytic Adenovirus: Coming of Age.

Authors:  Alexander T Baker; Carmen Aguirre-Hernández; Gunnel Halldén; Alan L Parker
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.